Philip Wagenheim - 20 Mar 2026 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Director
Issuer ticker: IMNM
Reported as of: 20 Mar 2026
Net transaction value: -$1,335,626
SEC form: 4
Accepted by SEC: 23 Mar 2026, 21:23:29 UTC
Prior SEC filing: 18 Mar 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Philip Wagenheim filed Form 4 for Immunome Inc. (IMNM) on 23 Mar 2026.

Key facts

This page summarizes Philip Wagenheim's Form 4 filing for Immunome Inc. (IMNM).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 21:23.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$1,335,626.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405684 Primary reporting owner

WAGENHEIM PHILIP

Relationship: Director
Address: C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Signature date: 23 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNM transaction

Common Stock

Sale

Transaction value: $753,296
Shares: -36,800
Change %: -9.1%
Price: $20.47
Shares after: 369,347
Date: 20 Mar 2026
Ownership: Direct
Footnotes: F1

IMNM transaction

Common Stock

Sale

Transaction value: $582,330
Shares: -28,200
Change %: -7.6%
Price: $20.65
Shares after: 341,147
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The weighted average sale price for the transaction report was $20.47, and the range of prices were between $20.07 and $20.96, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F2

The weighted average sale price for the transaction report was $20.65, and the range of prices were between $20.15 and $20.84, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.